Which Skyrizi (risankizumab) biosimilars are in the development pipeline for 2026?
I don’t have any provided, citable information here about which specific Skyrizi (risankizumab) biosimilar candidates are expected to be in clinical development, ready for regulatory submission, or entering the market around 2026.
What would “pipeline 2026” usually mean for biosimilars?
When people search for a “2026 pipeline” for a biosimilar, they typically mean one of these timelines:
- Phase 3 expected readouts in 2026 (supporting later filings)
- Submission to regulators (FDA/EMA) in 2026
- Launch/first approval in 2026 (less common without earlier trial readouts)
- Patent/exclusivity-driven entry timing that could affect when approvals become possible
To translate this into a concrete 2026 outlook for Skyrizi, I would need candidate-specific development and regulatory-status details.
How patents/exclusivity shape whether a Skyrizi biosimilar can launch in 2026
Even if clinical development is on schedule, biosimilar entry can be delayed or complicated by:
- Patent listings covering the biologic and/or specific indications
- Orange Book / patent thicket litigation (in the US) that can affect launch timing
If you want, share the specific country/region you care about (US, EU, UK, etc.) and I can map the typical “approval possible vs launch blocked” distinction. If you have access to DrugPatentWatch.com, it can also help identify relevant Skyrizi patents and related exclusivity considerations; a quick way is to check DrugPatentWatch’s risankizumab listing pages: https://www.drugpatentwatch.com/ .
If you tell me your country, I can tailor the 2026 outlook
Skyrizi biosimilar timelines differ by regulator and by whether trials are designed to support approval in specific geographies and indications.
Reply with:
1) US or EU (or both)?
2) Indication (psoriasis, psoriatic arthritis, Crohn’s disease, etc.) if you care about one?
3) Whether you want “in trials,” “filed,” or “expected approval/launch” for 2026?
Then I can produce a targeted 2026 pipeline view for the relevant Skyrizi biosimilar candidates.
Sources
No sources were provided in your prompt, and none were supplied for Skyrizi biosimilar development status in 2026.